| pubmed-article:2452773 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C0006610 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C1306673 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C0445204 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:2452773 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:2452773 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2452773 | pubmed:dateCreated | 1988-6-20 | lld:pubmed |
| pubmed-article:2452773 | pubmed:abstractText | Preoperative serum CA 125 levels were determined for 36 patients with Stage I and II ovarian carcinoma. Levels ranged from 9 to 1962 U/ml with a mean of 216 U/ml. In Stage I patients, CA 125 levels averaged 133 U/ml and in Stage II patients 382 U/ml. Nine of 24 Stage I (38%) and 9 of 12 Stage II patients (75%) had CA 125 levels in excess of 65 U/ml in a population somewhat overrepresented in mucinous tumors. Patients with non-mucinous neoplasms had CA 125 elevations more often--in 75% of the cases--than those with mucinous tumors. A larger study will be required to more precisely estimate the fraction of early stage patients with elevated preoperative serum CA 125 levels; however, this investigation demonstrates an assay sensitivity minimally adequate to initiate a pilot evaluation of serum CA 125 levels in a population at risk for ovarian carcinoma. | lld:pubmed |
| pubmed-article:2452773 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452773 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2452773 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452773 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2452773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452773 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2452773 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2452773 | pubmed:month | May | lld:pubmed |
| pubmed-article:2452773 | pubmed:issn | 0090-8258 | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:ZurawskiV... | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:OhmiKK | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:KnappR CRC | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:EinhornNN | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:MortelRR | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:BartT HTH | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:RittsR EREJr | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:KenemansPP | lld:pubmed |
| pubmed-article:2452773 | pubmed:author | pubmed-author:MalkasianGG | lld:pubmed |
| pubmed-article:2452773 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2452773 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:2452773 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2452773 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2452773 | pubmed:pagination | 7-14 | lld:pubmed |
| pubmed-article:2452773 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:meshHeading | pubmed-meshheading:2452773-... | lld:pubmed |
| pubmed-article:2452773 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:2452773 | pubmed:articleTitle | An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. | lld:pubmed |
| pubmed-article:2452773 | pubmed:affiliation | Gynecologic Oncology Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115. | lld:pubmed |
| pubmed-article:2452773 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2452773 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2452773 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2452773 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2452773 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2452773 | lld:pubmed |
